Archive: Company News
Company News: Curetis Acquires Real-Time qPCR Platform from Carpegen and Systec
– Gyronimo Platform offers rapid, quantitative cartridge-based sample-to-answer molecular diagnostic testing
– Gyronimo to be fully integrated into Unyvero Platform and suite of products
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced the acquisition of the real-time qPCR-based Gyronimo Platform from Carpegen GmbH and Systec GmbH, joint owners of the platform.
Company News: #investEU – Curetis obtains EIB debt financing totaling up to EUR 25 million to further expand its diagnostic platform
– European Investment Bank (EIB) provides EUR 10 million immediately, with a further EUR 15 million available upon meeting certain milestones
– Transaction is guaranteed by the European Fund for Strategic Investments (EFSI), the heart of the Investment Plan for Europe
– Financing allows strategic expansion and further development of Unyvero Platform
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, and the European Investment Bank (EIB) today announced that the EIB granted Curetis a EUR 25 million senior, unsecured loan. The financing is the first growth capital loan under the European Growth Finance Facility (EGFF), launched in November 2016.
Company News: ISA Pharmaceuticals Advances Personalized Cancer Treatment
– Next-generation immunotherapy called MyISA® for individual cancer patients
ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company, has joined the recently established Tumor neoantigEn SeLection Alliance (TESLA), a global cancer neoantigen alliance forged by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute, which was announced on December 1st, 2016.
Company News: Curetis Publishes Business and Financial Update for the First Nine Months 2016
– U.S. FDA trial completed with excellent top-line data
– Leading position in genetic antimicrobial resistance biomarker testing strengthened by GEAR acquisition
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today published a business and financial update for the first nine months ended September 30, 2016 and provided an outlook to coming months.